We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Clinical Trials with DBI, a New Nonsulfonylurea Oral Hypoglycemic Agent

AMA Arch Intern Med. 1958;102(1):25-31. doi:10.1001/archinte.1958.00260190027004.
Text Size: A A A
Published online


The current medical literature contains many reports of studies with oral hypoglycemic agents.1-3 These substances thus far have been sulfonylurea derivatives with blood-sugar-lowering ability in certain types of diabetes. Within the last year studies were started with a new group of compounds classified as formamidinyliminoureas. These drugs are biguanides, not to be confused with the diguanidines, which include Synthalin (guanidine-deca-methylene-guanidine) (Fig. 1). They also have no structural relationship to either carbutamide or tolbutamide and have no sulfonyl radical in their formulae. Ungar et al.4 recently reported that one of these agents, phenethylformamidinyliminourea hydrochloride, was effective orally in both normal and alloxandiabetic animals. He also reported5 the uptake of glucose by a rat diaphragm preparation. Williams6 reported a hypoglycemic effect in animals, and Nielsen et al.7 stated that this hypoglycemic effect was observed in depancreatized animals. Pomeranze8 first demonstrated successful hypoglycemic effects in clinical trials with patients.

This present report is


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

28 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.